Bedaquiline contraindications: Difference between revisions

Jump to navigation Jump to search
Chetan Lokhande (talk | contribs)
No edit summary
Gerald Chi (talk | contribs)
mNo edit summary
Line 3: Line 3:
{{CMG}}{{AE}}; {{chetan}}
{{CMG}}{{AE}}; {{chetan}}


 
==Contraindications==
None.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = SIRTURO (BEDAQUILINE FUMARATE) TABLET [JANSSEN PRODUCTS, LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1534c9ae-4948-4cf4-9f66-222a99db6d0e#nlm34089-3 | publisher =  | date =  | accessdate = 23 December 2013 }}</ref>
None.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = SIRTURO (BEDAQUILINE FUMARATE) TABLET [JANSSEN PRODUCTS, LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1534c9ae-4948-4cf4-9f66-222a99db6d0e#nlm34089-3 | publisher =  | date =  | accessdate = 23 December 2013 }}</ref>



Revision as of 14:03, 24 December 2013

Bedaquiline
SIRTURO® FDA Package Insert
Description
Clinical Pharmacology
Indications and Usage
Microbiology
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: ; Chetan Lokhande, M.B.B.S [2]

Contraindications

None.[1]

References

  1. "SIRTURO (BEDAQUILINE FUMARATE) TABLET [JANSSEN PRODUCTS, LP]". Retrieved 23 December 2013.

Adapted from the FDA Package Insert.